Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABS-002
- Development stage
- Preclinical
- Lead developer
- Alpha Biomedical
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
ABS-002 is a mesenchymal stem cell (MSC) therapy under development by Alpha Biomedical for the treatment of osteoarthritis. Currently in the preclinical stage, the therapy leverages the regenerative and immunomodulatory properties of MSCs to address joint degeneration. MSCs are hypothesized to promote cartilage repair and reduce synovial inflammation through the secretion of paracrine factors and direct cell-to-cell interactions, potentially offering a disease-modifying approach for patients with osteoarthritis.
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)
Beyond the preview
Go deeper on ABS-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABS-002.